• Publications
  • Influence
Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease
Coexpression of Sp1 and TAFII130 in cultured striatal cells from wild-type and HD transgenic mice reverses the transcriptional inhibition of the dopamine D2 receptor gene caused by mutant huntingtin, as well as protects neurons from huntingtin-induced cellular toxicity. Expand
The Parkinson Progression Marker Initiative (PPMI)
The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding ofExpand
Lighting up the Senses: FM1-43 Loading of Sensory Cells through Nonselective Ion Channels
A novel mechanism for vital fluorescent dye entry into sensory cells and neurons: permeation through ion channels is described, suggesting that organic cationic dyes are able to pass through a number of different sensory channels. Expand
Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat
MGluR1 was the only mGluR message prominently expressed in the dopaminergic neurons of the substantia nigra pars compacta, suggesting the involvement of this receptor in the regulation of dopamine release from nigrostriatal terminals. Expand
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
This is the first demonstration of the benefit of continuous levodopa delivery in a double-blind controlled study and offers a promising option for control of advanced Parkinson's disease with motor complications. Expand
Molecular markers of early Parkinson's disease based on gene expression in blood
Gene expression signals measured in blood can facilitate the development of biomarkers for PD, and the molecular multigene marker here identified is associated with risk of PD in 66 samples of the training set comprising healthy and disease controls. Expand
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Initial pramipexole treatment resulted in significantly less development of wearing off, dyskinesias, or on-off motor fluctuations compared with levodopa (51%) (hazard ratio, 0.45; 95% confidence interval [CI], 0.66), and the mean improvement in total UPDRS score from baseline to 23.5 months was greater in thelevodopa group than in the pramipingxole group (9.5 points; P<.001). Expand
The pathophysiological basis of dystonias
Dystonia offers a window into the mechanisms whereby subtle changes in neuronal function, particularly in sensorimotor circuits that are associated with motor learning and memory, can corrupt normal coordination and lead to a disabling motor disorder. Expand
Monitoring Motor Fluctuations in Patients With Parkinson's Disease Using Wearable Sensors
This paper presents the results of a pilot study to assess the feasibility of using accelerometer data to estimate the severity of symptoms and motor complications in patients with Parkinson'sExpand
Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
Chronic treatment of lesioned rats with L-dopa normalized the alterations in the abundance and subunit composition of the NMDA receptors in striatal membranes, and produced striking hyperphosphorylation, both of NR1 at serine residues, and NR2A andNR2B at tyrosine residues. Expand